BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
TL;DR
BioMed X and Novo Nordisk's collaboration offers a competitive edge in developing oral peptide delivery technologies, potentially revolutionizing treatment accessibility and efficacy.
The project focuses on creating oral formulation technologies for prolonged peptide retention in the gut, aiming to enhance drug absorption and bioavailability through innovative research.
This partnership aims to improve patient compliance and quality of life by making peptide-based therapeutics more accessible and effective through advanced oral delivery methods.
A groundbreaking collaboration between BioMed X and Novo Nordisk seeks to tackle the challenge of oral peptide delivery, promising a leap forward in medical treatment options.
Found this article helpful?
Share it with your network and spread the knowledge!
BioMed X, an independent biomedical research institute, and Novo Nordisk, a global healthcare leader, have announced a collaborative effort to overcome one of the most pressing challenges in drug development: the oral delivery of therapeutic peptides. This partnership, centered around the project 'Prolonged Retention of Oral Peptide Formulations in the Gut', seeks to develop new technologies that enhance the absorption and bioavailability of peptide-based drugs by ensuring their prolonged retention in the lower small intestine.
The initiative addresses a significant hurdle in modern medicine, where the effectiveness of oral peptide formulations is often limited by low intestinal permeability and rapid gastrointestinal transit. By focusing on site-specific, prolonged retention of tablets or capsules, the research aims to facilitate continuous release and efficient absorption of peptides, thereby improving patient compliance without compromising safety or causing gastrointestinal obstruction.
The research team, to be hosted at BioMed X in Heidelberg, Germany, will benefit from the combined expertise and resources of both organizations. Researchers interested in contributing to this groundbreaking project are encouraged to submit their proposals via the BioMed X Career Space before October 12, 2025.
Dr. Christian Tidona, CEO of BioMed X, expressed enthusiasm about the collaboration, highlighting the potential impact on patients' lives through the development of orally available peptide drugs. Similarly, Stephen Buckley, Scientific Vice President at Novo Nordisk, underscored the company's commitment to pushing the boundaries of science through both internal and external innovation, viewing this project as a promising opportunity to advance oral formulation technologies.
This collaboration between BioMed X and Novo Nordisk represents a significant step forward in the quest to make peptide-based therapies more accessible and effective for patients worldwide. By leveraging innovative research and development strategies, the partnership aims to set new standards in the oral delivery of therapeutic peptides, with far-reaching implications for the treatment of chronic diseases.
Curated from Reportable
